Cannara Biotech Inc. reported record-breaking financial results for Q3 2025, with total revenues of $27.3 million, a 40% increase from the prior year. Gross profit before fair value adjustments rose to $12.1 million, a 110% increase. Adjusted EBITDA reached a record high of $7.6 million, up 173%. Operating cash flow increased to $13.9 million, and free cash flow to $11.7 million.

Extensive research and development efforts at Cannara have led to a 26% yield improvement, increasing annual capacity to 50,000 kg. The company received approval for 5 SKUs for the Quebec vape category launch, representing 20% of all accepted in-store SKUs by the province.

Cannara reduced the interest rate on its BMO credit facility by 50 basis points, further reduced by 25 basis points post-quarter end. The cost of debt on the credit facility is now below 6%. All financial results are reported in Canadian dollars.

Cannara’s financial performance demonstrates its strength, with gross profit before fair value adjustments rising 110% to $12.1 million in Q3 2025. Adjusted EBITDA reached $7.6 million, a 173% increase. Operating cash flow surged to $13.9 million, and free cash flow to $11.7 million.

The company achieved a 26% yield improvement through cultivation optimization, increasing annual capacity to 50,000 kg. Approval for 5 SKUs for the Quebec vape category launch positions Cannara for continued growth. Interest rate reduction on the BMO credit facility to below 6% enhances financial position.

Cannara’s focus on disciplined cost management and operational competencies drove significant financial growth. Gross profit margins increased to 44% in Q3 2025. Adjusted EBITDA rose to a record high of $7.6 million, and operating cash flow reached $13.9 million. Free cash flow surged to $11.7 million.

The company’s operational highlights include optimizing cultivation procedures for a 26% yield improvement, reaching its Fiscal 2026 cultivation target ahead of schedule. Product launches include a unique sub-30% THC offering for Quebec and new genetics and products in the portfolio.

Cannara’s national market share increased in various provinces, demonstrating successful performance across all markets. Gross cannabis revenues rose to $37.8 million in Q3 2025. Total revenues increased to $27.3 million, and gross profit before fair value adjustments reached $12.1 million. Operating income rose to $6.8 million.

In Q3 2025, Cannara delivered strong financial results with a 40% increase in total revenues to $27.3 million. Gross profit before fair value adjustments rose to $12.1 million, representing a 110% increase. The company achieved a record-high Adjusted EBITDA of $7.6 million. Operating cash flow surged to $13.9 million, and free cash flow increased to $11.7 million.

Read more at GlobeNewswire: Cannara Biotech Delivers Highest Revenue and Profitability